News coverage about Achillion Pharmaceuticals (NASDAQ:ACHN) has been trending somewhat positive on Monday, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Achillion Pharmaceuticals earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.7872984908912 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
- Investor’s Roundup (Volatility Analysis) – Achillion Pharmaceuticals, Inc., (NASDAQ: ACHN) – Stock Watch (stocksnewstimes.com)
- Achillion Pharmaceuticals Inc (NASDAQ: ACHN) – Is the Stock In Play? – Alpha Beta Stock (alphabetastock.com)
- Hot Stock’s Trend Recap – Achillion Pharmaceuticals, Inc., (NASDAQ: ACHN) – Stock Watch (stocksnewstimes.com)
- Commit To Buy Achillion Pharmaceuticals At $3, Earn 12.9% Annualized Using Options (nasdaq.com)
- Hottest Stocks Now: ConocoPhillips (NYSE:COP), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), PPL Corporation … – Market Breaking Point (press release) (journalfinance.net)
Shares of Achillion Pharmaceuticals (NASDAQ ACHN) traded up 3.31% during midday trading on Monday, hitting $4.06. 1,120,951 shares of the stock traded hands. The stock has a 50 day moving average of $4.22 and a 200 day moving average of $4.26. Achillion Pharmaceuticals has a 1-year low of $3.15 and a 1-year high of $6.56. The company’s market capitalization is $555.25 million.
Achillion Pharmaceuticals (NASDAQ:ACHN) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.16). During the same period last year, the business earned ($0.14) EPS. Equities research analysts predict that Achillion Pharmaceuticals will post ($0.66) earnings per share for the current fiscal year.
A number of equities research analysts have weighed in on ACHN shares. Zacks Investment Research downgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. BidaskClub downgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 25th. ValuEngine downgraded shares of Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Monday, September 11th. Robert W. Baird restated a “neutral” rating and issued a $4.00 target price (down previously from $5.00) on shares of Achillion Pharmaceuticals in a research note on Tuesday, September 12th. Finally, Chardan Capital restated a “neutral” rating on shares of Achillion Pharmaceuticals in a research note on Sunday, September 17th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $6.75.
WARNING: “Achillion Pharmaceuticals (ACHN) Receiving Somewhat Positive Media Coverage, Analysis Shows” was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.com-unik.info/2017/10/30/achillion-pharmaceuticals-achn-receiving-somewhat-positive-media-coverage-analysis-shows.html.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
What are top analysts saying about Achillion Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Achillion Pharmaceuticals Inc. and related companies.